| What it is | Colchicine is one of three drugs tested in this study, evaluated under a crossover design in patients with isolated skin-limited vasculitis. | Dapsone is another investigational option evaluated in serial treatment periods in the same trial. | Azathioprine is the third investigational therapy administered across study stages in the crossover design. | Usual clinical practice for isolated skin vasculitis often involves symptomatic care, topical therapies or short-course systemic corticosteroids depending on severity. |
|---|
| Role in trial | Assigned as one of the repeated treatments participants receive under randomised crossover stages. | Randomized into serial treatment periods as one of the study drugs. | Given to participants in one of the crossover stages as an investigational option. | Not part of the study regimen; reflects routine approaches outside the trial. |
|---|
| Primary use | Being evaluated for efficacy in treating skin-limited vasculitis lesions. | Tested as an active treatment for isolated cutaneous vasculitis in the trial. | Assessed as a potential therapeutic agent for skin-limited vasculitis. | Typically manages symptoms or flares using topical treatments or systemic steroids depending on disease activity. |
|---|
| How it is given | Given orally at 0.6 mg twice daily as one treatment period. | Administered orally at 150 mg per day during its assigned period. | Given orally at approximately 2 mg per kg per day in its crossover period. | Varies; may include topical creams or systemic steroids taken for short periods. |
|---|
| Evidence status | Efficacy in skin‑limited vasculitis remains under investigation; no published results yet. | Efficacy data for dapsone in this population is not yet available from the trial. | Azathioprine’s effectiveness will be evaluated by the trial; results not yet published. | Current therapies such as topical or systemic steroids are broadly used although high‑quality evidence for skin‑limited disease is limited. |
|---|
| Important risks | Safety profile in this study population is not yet established. | Risks in this study are still being determined; study ongoing. | Safety of azathioprine in this skin‑limited vasculitis setting is under evaluation; not yet reported. | Topical treatments have low systemic risk; systemic steroids may involve side effects when used repeatedly. |
|---|
| Important limitations | Results are pending and applicability will depend on tolerability and patient preference. | Expected findings remain unavailable; outcomes may vary by individual drug tolerability. | No published efficacy or safety data yet; generalizability to all patients with skin‑limited vasculitis is untested. | Evidence for standard treatment efficacy is weak in this subgroup and may lack randomized trial support. |
|---|
| Patient impact | Not yet known; trial has not reported outcomes affecting quality of life or symptom remission. | Not yet known; patient‑reported responses are still to be assessed. | Not yet known; pending trial results include quality‑of‑life and symptom assessments. | May alleviate symptoms by reducing flares; high‑quality evidence in skin‑limited cases is scarce. |
|---|